Rce1: mechanism and inhibition
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Ras converting enzyme 1 (Rce1) is an integral membrane endoprotease localized to the endoplasmic reticulum that mediates the cleavage of the carboxyl-terminal three amino acids from CaaX proteins, whose members play important roles in cell signaling processes. Examples include the Ras family of small GTPases, the γ-subunit of heterotrimeric GTPases, nuclear lamins, and protein kinases and phosphatases. CaaX proteins, especially Ras, have been implicated in cancer, and understanding the post-translational modifications of CaaX proteins would provide insight into their biological function and regulation. Many proteolytic mechanisms have been proposed for Rce1, but sequence alignment, mutational studies, topology, and recent crystallographic data point to a novel mechanism involving a glutamate-activated water and an oxyanion hole. Studies using in vivo and in vitro reporters of Rce1 activity have revealed that the enzyme cleaves only prenylated substrates and the identity of the a2 amino residue in the Ca1a2X sequence is most critical for recognition, preferring Ile, Leu, or Val. Substrate mimetics can be somewhat effective inhibitors of Rce1 in vitro. Small-molecule inhibitor discovery is currently limited by the lack of structural information on a eukaryotic enzyme, but a set of 8-hydroxyquinoline derivatives has demonstrated an ability to mislocalize all three mammalian Ras isoforms, giving optimism that potent, selective inhibitors might be developed. Much remains to be discovered regarding cleavage specificity, the impact of chemical inhibition, and the potential of Rce1 as a therapeutic target, not only for cancer, but also for other diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Comprehensive Survey of Ras Mutations in Cancer
Prior, I. A., Lewis, P. D., & Mattos, C. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2612 · Cited by 2,063 · cited 5×
“Assay type Reporter Sequencea Detection method In vivo GFP-Ras (H, N, K4a, K4b) (∼45 kDa) GFP-H-Ras-CVLS GFP-N-Ras-CVVM GFP-KRas4a-CIIM GFP-K-Ras4b-CVIM Cell-based fluorescence GFP-Ras2p (∼60kDa) GFP-Ras2p-CIIS Cell-based fluorescence a-factor precursor (36-mer) Mature a-factor peptide-CVIA Bioactivity In vitro a-fact…”
BackgroundInfluentialClark, J. D., Lin, L.-L., Kriz, R. W., Ramesha, C. S., Sultzman, L. A., Lin, A. Y., Milona, N., & Knopf, J. L. (1991) · Cell · doi:10.1016/0092-8674(91)90556-e · Cited by 1,688
Differential Localization of Rho Gtpases in Live Cells
Michaelson, D., Silletti, J., Murphy, G., D'Eustachio, P., Rush, M., & Philips, M. R. (2001) · The Journal of Cell Biology · doi:10.1083/jcb.152.1.111 · Cited by 679 · cited 1×
“Rho-family proteins (i.e. Cdc42, Rac1, Rac2, and RhoA) are cytosolic, and this localization is independent of Rce1 activity (Michaelson et al. 2001, 2005).”
BackgroundTargeting protein prenylation for cancer therapy
Berndt, N., Hamilton, A. D., & Sebti, S. M. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3151 · Cited by 614 · cited 1×
“Because Ras function optimally requires post--translational modification, there is intense interest for developing therapeutic inhibitors for all modification steps (Silvius 2002; Winter-Vann and Casey 2005; Konstantinopoulos et al. 2007; Berndt et al. 2011; Cox et al. 2015; Wang and Casey 2016).”
BackgroundRho Family GTPase modification and dependence on CAAX motif-signaled posttranslational modification
Roberts, P. J., Mitin, N., Keller, P. J., Chenette, E. J., Madigan, J. P., Currin, R. O., Cox, A. D., Wilson, O., Kirschmeier, P., & Der, C. J. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m800882200 · Cited by 362 · cited 2×
“More commonly, GFP-tagging of Ras and other Ras-related GTPases is used to assess the role of Rce1 in regulating small GTPase subcellular localization (Boyartchuk et al. 1997; Choy et al. 1999; Michaelson et al. 2005; Manandhar et al. 2007; Bracha-Drori et al. 2008; Roberts et al. 2008; Mokry et al. 2009; Hanker et al…”
BackgroundPost-prenylation-processing enzymes as new targets in oncogenesis
Winter-Vann, A. M., & Casey, P. J. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1612 · Cited by 357
Targeting RAS Membrane Association: Back to the Future for Anti-RAS Drug Discovery?
Cox, A. D., Der, C. J., & Philips, M. R. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3214 · Cited by 351
Cited by
RAS-targeted therapies: is the undruggable drugged?
Moore, A. R., Rosenberg, S. C., McCormick, F., & Malek, S. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0068-6 · Cited by 1,103
KRAS G12C Game of Thrones, which direct KRAS inhibitor will claim the iron throne?
Nagasaka, M., Li, Y., Sukari, A., Ou, S.-H. I., Al-Hallak, M. N., & Azmi, A. S. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.101974 · Cited by 185
(2023) · doi:10.1128/jb.00173-23 · Cited by 4
Metadata
- Authors
- Hampton, S. E., Dore, T. M., & Schmidt, W. K.
- Venue
- Critical Reviews in Biochemistry and Molecular Biology
- Publisher
- Informa UK Limited
- Published
- 2018-02-09
- Volume
- 53
- Issue
- 2
- Pages
- 157-174
- ISSN
- 0045-6411 (ISSN-L)
- 1040-9238
- 1549-7798
- OpenAlex
- W2791694385
- Cited by
- 53
- References
- 7
- FWCI
- 0.51
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Rce1: mechanism and inhibition. https://app.cochat.ai/papers/10.1080/10409238.2018.1431606
- The paper
- Hampton, S. E., Dore, T. M., & Schmidt, W. K. (2018). Rce1: mechanism and inhibition. Critical Reviews in Biochemistry and Molecular Biology. https://doi.org/10.1080/10409238.2018.1431606
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.